PT - JOURNAL ARTICLE AU - Yu Wu AU - I Tang AU - Chung Liu AU - Tsai Luo AU - Wuu Lin TI - Evaluating the therapeutic potential of 188Re-HYNIC-trastuzumab(Herceptin) for human breast cancer in the animal model DP - 2009 May 01 TA - Journal of Nuclear Medicine PG - 1590--1590 VI - 50 IP - supplement 2 4099 - http://jnm.snmjournals.org/content/50/supplement_2/1590.short 4100 - http://jnm.snmjournals.org/content/50/supplement_2/1590.full SO - J Nucl Med2009 May 01; 50 AB - 1590 Objectives Her-2/neu protein over expression has been identified in 10%~34% of invasive breast cancers. Trastuzumab(Herceptin) is a humanized IgG1 monoclonal antibody that recognizes HER-2/neu receptor. We developed a new therapeutic radiopharmaceutical 188Re-labelled trastuzumab (Herceptin) through a bifunctional chelator, hydrazine nicotinamide (HYNIC). We test the ability of 188Re-HYNIC-Herceptin complex to recognize the Her-2/neu which over expression in human breast cancer cell in vitro and in vivo. Methods We synthesized HYNIC-Herceptin and labeled with Re-188. The immunoreactivity of HYNIC-Herceptin was evaluated by a receptor-binding assay using BT-474 human breast cancer cell line. Biodistribution, microSPECT/CT imaging and therapeutic efficacy experiments were performed in female SCID mice bearing BT-474 human breast cancer cell line. We treated these mice 188Re-HYNIC-trastuzumab(Herceptin) once two weeks and tumors were measured for length, width, and height once a week for 4 month. Results The biodistribution data show that the tumor uptake of radioactivity increased from 0.4±0.22 %ID/g at 1h to 2.1±0.97 %ID/g at 48h postinjection of 188Re-HYNIC-trastuzumab (Herceptin). MicroSPECT /CT images show that tumor uptake is visualized as well as high accumulation in the tumor, kidneys and spleen. Therapeutic efficacy tumor size measurements showed that tumor growth was significantly inhibited by treating with 188Re-HYNIC-trastuzumab(Herceptin). Conclusions This study proved that 188Re-HYNIC-Herceptin is a potential therapeutic radiopharmaceutical for breast cancer. We still need to perform more advanced studies to prove its efficacy.